Back to top
more

Amicus Therapeutics (FOLD)

(Delayed Data from NSDQ)

$6.79 USD

6.79
3,988,868

-0.14 (-2.02%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $6.80 +0.01 (0.15%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

by Zacks Equity Research

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Zacks Equity Research

Synlogic, Inc. (SYBX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Synlogic, Inc. (SYBX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.

Zacks Equity Research

Zacks.com featured highlights include Amicus Therapeutics, Genius Sports and Viad

by Zacks Equity Research

Amicus Therapeutics, Genius Sports and Viad are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Stocks Worth a Watch for Solid Earnings Acceleration

by Tirthankar Chakraborty

Some of the notable companies to have witnessed solid earnings acceleration as of now are Amicus Therapeutics (FOLD), Genius Sports (GENI) and Viad (VVI).

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Down 6.8% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss

by Zacks Equity Research

FATE reports a lower-than-expected loss on a decline in operating expenses in the second quarter of 2023.

Zacks Equity Research

bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues

by Zacks Equity Research

bluebird bio (BLUE) reports better-than-expected results in the second quarter of 2023 due to product revenues now being generated from Skysona (elivaldogene autotemcel) and Zynteglo (betibeglogene autotemcel).

Zacks Equity Research

Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25% and 5.51%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Earnings Season Could Be Great for Amicus Therapeutics (FOLD)

by Zacks Equity Research

Amicus Therapeutics (FOLD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Zacks.com featured highlights include First Watch Restaurant Group, VersaBank and Amicus Therapeutics

by Zacks Equity Research

First Watch Restaurant Group, VersaBank and Amicus Therapeutics are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Top Breakout Stocks to Invest in for Excellent Returns

by Tirthankar Chakraborty

First Watch Restaurant Group (FWRG), VersaBank (VBNK), and Amicus Therapeutics (FOLD) have been selected as the breakout stocks for today.

Zacks Equity Research

Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug

by Zacks Equity Research

Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.

Zacks Equity Research

Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Company News for May 11, 2023

by Zacks Equity Research

Companies in The news Are: VSH,COHRICL,FOLD

Zacks Equity Research

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Icosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Icosavax, Inc. (ICVX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.